OOS – Page 48 – Pharma.Tips

Punch tip damage during high-speed compression – FDA inspection observation risk

Punch Tip Integrity Issues During High-Speed Tablet Compression: An Inspection Risk In high-speed tablet production, punch tip damage is a recurring problem that can compromise tablet integrity and ultimately lead…

Turret speed instability during inspection prep – FDA inspection observation risk

Addressing Turret Speed Instability During Inspection Preparation: Strategies for Compliance and Prevention In the fast-paced environment of pharmaceutical manufacturing, equipment failures can lead to significant downtime, regulatory scrutiny, and potential…

Tablet weight variation during inspection prep – FDA inspection observation risk

Addressing Tablet Weight Variation During Inspection Preparation: Strategies for Success In pharmaceutical manufacturing, maintaining consistent tablet weight during inspection prep is not just a quality issue; it’s also a regulatory…

CCIT failure during packaging – regulatory risk assessment

Regulatory Risk Assessment of CCIT Failures During Packaging In the fast-paced world of pharmaceutical manufacturing, the failure of container closure integrity testing (CCIT) during the packaging process can pose significant…

Viscosity variation during storage – QA investigation failure

Investigation of Viscosity Variations During Storage in Pharmaceuticals Viscosity variation during storage is a frequent issue observed in pharmaceutical manufacturing, particularly with suspensions and syrups. Such nonconformance can prompt Out…

Phase separation after temperature excursion – QA investigation failure

Investigating Phase Separation After Temperature Excursion: A Comprehensive QA Approach In the world of pharmaceutical manufacturing, deviations from established protocols can lead to significant quality concerns and product failures. One…

Tube leakage after packaging change – inspection readiness risk

Investigating Tube Leakage Issues Following Packaging Change: Ensuring Inspection Readiness In the fast-paced world of pharmaceutical manufacturing, packaging changes are a common necessity. However, they can also introduce significant risks,…

pH drift on storage at accelerated conditions – stability investigation failure

Stability Investigation of pH Drift During Storage at Accelerated Conditions Issues related to pH drift during storage at accelerated conditions represent significant risks in pharmaceutical manufacturing. Such deviations can result…

Physical appearance change during shelf-life extension – stability investigation failure

Stability Investigation Failures: Addressing Physical Appearance Changes During Shelf-Life Extension The occurrence of physical appearance changes during the shelf-life extension of pharmaceutical products can indicate underlying issues that may lead…

Impurity increase during shelf-life extension – CAPA and shelf-life justification gap

Addressing Increased Impurities in Extended Product Shelf-Life: A Comprehensive Investigation Guide In the pharmaceutical manufacturing landscape, the integrity of product quality during shelf-life extension poses significant challenges. An increase in…

Assay degradation trend after market storage – CAPA and shelf-life justification gap

Addressing Assay Degradation Trends Post-Market Storage: An Investigation Approach In the pharmaceutical industry, ensuring product integrity throughout its shelf life is paramount. Recently, there have been reported concerns regarding assay…

Preservative loss at long-term stability – regulatory inspection risk

Understanding Preservative Loss During Long-Term Stability and Its Regulatory Implications In today’s highly regulated pharmaceutical environment, any deviation from expected product stability can trigger significant concerns, particularly when it relates…